|
시장보고서
상품코드
1907957
멜록시캄 시장 : 제품 유형별, 적응증별, 유효성분 함유량별, 투여경로별, 약제유형별, 연령층별, 최종사용자별, 유통채널별, 지역별Meloxicam Market, By Product Type, By Indication, By Dosage Strength, By Route of Administration, By Drug Type, By Age Group, By End User, By Distribution Channel, By Geography |
||||||
멜록시캄 시장은 2025년 81억 5,000만 달러로 평가되었고, 2032년까지 123억 4,000만 달러에 이를 것으로 예측됩니다. 2025년부터 2032년까지 연평균 복합 성장률(CAGR)6.1%로 성장할 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 81억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측기간 CAGR(2025-2032년) | 6.10% | 예측 금액(2032년) | 123억 4,000만 달러 |
세계의 멜록시캄 시장은 의약품 업계에서 중요한 부문을 차지하고 있으며, 널리 처방되는 비스테로이드성 항염증제(NSAID)인 본제의 제조, 유통, 소비를 포함합니다. 멜록시캄은 선택적 시클로옥시게나제-2(COX-2) 억제제로서 주로 변형성 관절증, 류마티스 관절염, 강직성 척추염과 같은 염증성 질환의 관리에서 기간 치료제로서의 지위를 확립하고 있습니다.
본 화합물은 COX-1 효소보다 COX-2를 우선적으로 저해하기 때문에 기존의 NSAID에 비해 우수한 위장내용성을 나타내며 헬스케어 종사자와 환자 모두에서 선호되는 선택이 되고 있습니다. 시장에는 경구 정제, 캡슐, 주사제, 외용제 등 다양한 제제가 존재하며 다양한 환자 요구와 치료 요건에 대응하고 있습니다.
세계적으로 고령화가 진행되고 퇴행성 관절 질환 및 염증성 질환의 위험이 높아지는 가운데 효과적인 통증 관리 솔루션에 대한 수요는 계속 증가하고 있습니다. 멜록시캄 시장은 제약 제조업체, 제네릭 의약품 제조업체, 의료 제공자, 규제 당국, 최종 사용자가 관련된 복잡한 에코시스템 중에서 전개되고 있으며, 이들 모든 관계자가 현대의 의약품 마켓플레이스에서의 역동적인 성장 궤도와 진화하는 경쟁 구도에 공헌하고 있습니다.
시장 역학
세계의 멜록시캄 시장은 여러 강력한 시장 성장 촉진요인에 의해 견인되어 다양한 지역에서 지속적인 성장세를 창출하고 있습니다. 주요 시장 성장 촉진요인은 급속하게 노화하는 세계 인구에 있습니다. 노화에 따라 골관절염, 류마티스 성 관절염 및 기타 염증성 근골격계 질환의 발병률이 본질적으로 증가하고 장기적인 약물 요법이 필요합니다.
게다가 생활습관병 증가, 좌식 생활 습관, 관절 열화를 초래하는 직업상의 위험인자의 존재가 대상 환자층을 크게 확대하고 있습니다. 이 약물의 뛰어난 안전성 프로파일, 특히 기존의 NSAIDs에 비해 위장 독성의 감소는 의사의 신뢰성과 환자의 복약 준수율을 높여 시장의 보급을 촉진하고 있습니다.
그러나 시장에는 현저한 제약도 존재합니다. 구체적으로는 NSAID의 승인과 감시를 규정하는 엄격한 규제 프레임워크, NSAID의 장기 사용에 따른 잠재적인 심혈관 위험, 생물학적 제제 및 신규 통증 관리법을 포함한 대체 항염증 요법과의 격렬한 경쟁 등을 들 수 있습니다. 특허 만료에 따른 후발 의약품과의 경쟁은 가격 압력과 브랜드 제품의 이익률 압축을 가져옵니다.
게다가 NSAID 관련 부작용에 대한 인식 증가와 신규 개인화된 의료 접근법은 전통적인 치료 패러다임에 어려움을 겪고 있습니다. 이러한 제약이 있음에도 불구하고 멜록시캄 시장 상황에는 큰 기회가 존재합니다. 신흥국의 노인 인구 확대는 미개척 시장 가능성을 보여주며 지속성 제제와 병용 요법을 포함한 신규 제제의 조사는 차별화의 기회를 제공합니다. 디지털 헬스와의 통합, 원격 의료 도입, 소비자를 위한 직접 판매 채널은 새로운 유통 경로와 환자 참여 기회를 창출하여 멜록시캄 시장의 지속적인 진화와 성장을 추진하고 있습니다.
이 보고서의 주요 특징
- 본 보고서는 세계의 멜록시캄 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 또한 각 부문의 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬을 설명합니다.
- 또한 시장 성장 촉진요인 및 억제요인과 기회, 신제품의 상시와 승인, 시장 동향, 지역별 전망, 주요기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 세계의 멜록시캄 시장에서 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음과 같은 매개변수를 기반으로 제공합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- '세계 멜록시캄 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자들은 세계의 멜록시캄 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 기업 합병·인수(M&A) 시나리오
- 업계 동향
제4장 세계의 멜록시캄 시장 : 제품 유형별(2020-2032년)
- 정제
- 캡슐
- 시럽·경구 현탁액
- 주사제
제5장 세계의 멜록시캄 시장 : 적응증별(2020-2032년)
- 골관절염
- 류마티스 관절
- 소아 류마티스 관절염
- 기타 근골격계 또는 염증성 질환
제6장 세계의 멜록시캄 시장 : 유효성분 함유량별(2020-2032년)
- 5mg
- 15mg
- 기타 투여 형태(예: 5mg, 10mg)
제7장 세계의 멜록시캄 시장 : 투여 경로별(2020-2032년)
- 경구
- 비경구
제8장 세계의 멜록시캄 시장 : 약제유형별(2020-2032년)
- 브랜드
- 제네릭
제9장 세계의 멜록시캄 시장 : 연령층별(2020-2032년)
- 성인
- 소아
- 고령자
제10장 세계의 멜록시캄 시장 : 최종 사용자별(2020-2032년)
- 병원 및 진료소
- 전문 클리닉
- 재택치료
- 연구기관 및 학술기관
- 기타(장기 요양 시설, 간병 시설 등)
제11장 세계의 멜록시캄 시장 : 유통 채널별(2020-2032년)
- 병원 약국
- 소매 약국
- 온라인 약국
제12장 세계의 멜록시캄 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제13장 경쟁 구도
- Cipla Ltd
- Unichem Laboratories Ltd
- Cadila Pharmaceuticals Ltd
- Lupin Ltd
- Aurobindo Pharma Ltd
- Reddy's Laboratories Ltd
- Olon SpA
- Dishman Carbogen Amcis
- Rochem International Inc
- HELM Portugal
- Hoventa Pharma
- Cerata Pharmaceuticals LLP
- Darshan Pharma Chem
- Zeon Pharma Industries India Pvt Ltd
- Swati Spentose
제14장 애널리스트의 제안
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map(COM)
제15장 참고문헌과 분석 방법
- 참고문헌
- 분석 방법
- Coherent Market Insights에 대해
Meloxicam Market is estimated to be valued at USD 8.15 Bn in 2025 and is expected to reach USD 12.34 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 8.15 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.10% | 2032 Value Projection: | USD 12.34 Bn |
The global meloxicam market represents a significant segment within the pharmaceutical industry, encompassing the production, distribution, and consumption of this widely prescribed nonsteroidal anti-inflammatory drug (NSAID). Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, has established itself as a cornerstone therapeutic agent for managing inflammatory conditions, primarily osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
The compound's preferential inhibition of COX-2 over COX-1 enzymes offers superior gastrointestinal tolerability compared to traditional NSAIDs, making it a preferred choice among healthcare practitioners and patients alike. The market encompasses various formulations including oral tablets, capsules, injectable solutions, and topical preparations, catering to diverse patient needs and therapeutic requirements.
With an aging global population increasingly susceptible to degenerative joint diseases and inflammatory disorders, the demand for effective pain management solutions continues to escalate. The meloxicam market operates within a complex ecosystem involving pharmaceutical manufacturers, generic drug producers, healthcare providers, regulatory authorities, and end users, all contributing to its dynamic growth trajectory and evolving competitive landscape in the contemporary pharmaceutical marketplace.
Market Dynamics
The global meloxicam market is propelled by several compelling drivers that collectively fuel its sustained growth momentum across diverse geographical regions. The primary driver stems from the rapidly aging global population, which inherently experiences higher incidence rates of osteoarthritis, rheumatoid arthritis, and other inflammatory musculoskeletal disorders requiring long-term pharmacological intervention.
Additionally, the increasing prevalence of lifestyle-related conditions, sedentary behaviors, and occupational hazards contributing to joint deterioration significantly expands the target patient population. The drug's favorable safety profile, particularly its reduced gastrointestinal toxicity compared to traditional NSAIDs, enhances physician confidence and patient compliance, thereby driving market adoption.
However, the market faces notable restraints including stringent regulatory frameworks governing NSAID approval and monitoring, potential cardiovascular risks associated with prolonged NSAID usage, and intense competition from alternative anti-inflammatory therapies including biologics and novel pain management modalities. Patent expirations have led to generic competition, creating pricing pressures and margin compression for branded products.
Furthermore, growing awareness of NSAID-associated adverse events and emerging personalized medicine approaches pose challenges to conventional treatment paradigms. Despite these constraints, substantial opportunities exist within the meloxicam market landscape. The expanding geriatric demographic in emerging economies presents untapped market potential, while ongoing research into novel formulations, including sustained-release preparations and combination therapies, offers differentiation prospects. Digital health integration, telemedicine adoption, and direct-to-consumer marketing channels create new distribution pathways and patient engagement opportunities, positioning the meloxicam market for continued evolution and growth.
Key Features of the Study
- This report provides in-depth analysis of the global meloxicam market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global meloxicam market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Cipla Ltd, Unichem Laboratories Ltd, Cadila Pharmaceuticals Ltd, Lupin Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd, Olon S.p.A, Dishman Carbogen Amcis, Rochem International Inc, HELM Portugal, Hoventa Pharma, Cerata Pharmaceuticals LLP, Darshan Pharma Chem, Zeon Pharma Industries India Pvt Ltd, and Swati Spentose.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global meloxicam market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global meloxicam market
Market Segmentation
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets
- Capsules
- Syrup or Oral Suspension
- Injectable Solutions
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Osteoarthritis
- Rheumatoid arthritis
- Juvenile rheumatoid arthritis (pediatric arthritis)
- Other musculoskeletal or inflammatory disorders
- Dosage Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 5 mg
- 15 mg
- Other strengths (e.g., 5 mg, 10 mg)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults
- Pediatric
- Geriatric
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Clinics
- Homecare Settings
- Research and Academic Institutes
- Others (long-term care, nursing homes, etc.)
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Cipla Ltd
- Unichem Laboratories Ltd
- Cadila Pharmaceuticals Ltd
- Lupin Ltd
- Aurobindo Pharma Ltd
- Reddy's Laboratories Ltd
- Olon S.p.A
- Dishman Carbogen Amcis
- Rochem International Inc
- HELM Portugal
- Hoventa Pharma
- Cerata Pharmaceuticals LLP
- Darshan Pharma Chem
- Zeon Pharma Industries India Pvt Ltd
- Swati Spentose
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Meloxicam Market, By Product Type
- Global Meloxicam Market, By Indication
- Global Meloxicam Market, By Dosage Strength
- Global Meloxicam Market, By Route of Administration
- Global Meloxicam Market, By Drug Type
- Global Meloxicam Market, By Age Group
- Global Meloxicam Market, By End User
- Global Meloxicam Market, By Distribution Channel
- Global Meloxicam Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Meloxicam Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Syrup or Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable Solutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Meloxicam Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Osteoarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rheumatoid arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Juvenile rheumatoid arthritis (pediatric arthritis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other musculoskeletal or inflammatory disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Meloxicam Market, By Dosage Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 5 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 15 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other strengths (e.g., 5 mg, 10 mg)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Meloxicam Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Meloxicam Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Meloxicam Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Meloxicam Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (long-term care, nursing homes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Meloxicam Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Meloxicam Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Unichem Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cadila Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Olon S.p.A
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dishman Carbogen Amcis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rochem International Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- HELM Portugal
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoventa Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cerata Pharmaceuticals LLP
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Darshan Pharma Chem
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zeon Pharma Industries India Pvt Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Swati Spentose
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
